An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas

Figure 2

Validation of the six-gene risk signature. (a–c) Kaplan–Meier survival analysis for IDH-mutant LGG patients based on the risk signature in the CGGA_693, TCGA, and CGGA_325 cohorts. (d–f) Risk scores distribution, survival status of each patient, and expression profile of the six-gene signature in the three cohorts. (g–i) The time-dependent ROC curve of the six-gene signature in the three cohorts.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)